Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/103517
Title: | Value of systematic genetic screening of patients with amyotrophic lateral sclerosis |
Authors: | Shepheard, Stephanie R. Parker, Matthew D. Cooper-Knock, Johnathan Verber, Nick S. Tuddenham, Lee Heath, Paul Beauchamp, Nick Place, Elsie Sollars, Elizabeth S.A. Turner, Martin R. Malaspina, Andrea Fratta, Pietro Hewamadduma, Channa Jenkins, Thomas M. McDermott, Christopher J. Wang, Dennis Kirby, Janine Cauchi, Ruben J. |
Authors: | Project MINE Consortium |
Keywords: | Genetic screening Amyotrophic lateral sclerosis -- Diagnosis Motor neurons Messenger RNA -- Metabolism |
Issue Date: | 2021 |
Publisher: | B M J Group |
Citation: | Shepheard, S. R., Parker, M. D., Cooper-Knock, J., Verber, N. S., Tuddenham, L., Heath, P., ... & Shaw, P. J. (2021). Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 92(5), 510-518. |
Abstract: | Objective: The clinical utility of routine genetic sequencing in amyotrophic lateral sclerosis (ALS) is uncertain. Our aim was to determine whether routine targeted sequencing of 44 ALS-relevant genes would have a significant impact on disease subclassification and clinical care. Methods: We performed targeted sequencing of a 44-gene panel in a prospective case series of 100 patients with ALS recruited consecutively from the Sheffield Motor Neuron Disorders Clinic, UK. All participants were diagnosed with ALS by a specialist Consultant Neurologist. 7/100 patients had familial ALS, but the majority were apparently sporadic cases. Results: 21% of patients with ALS carried a confirmed pathogenic or likely pathogenic mutation, of whom 93% had no family history of ALS. 15% met the inclusion criteria for a current ALS genetic-therapy trial. 5/21 patients with a pathogenic mutation had an additional variant of uncertain significance (VUS). An additional 21% of patients with ALS carried a VUS in an ALS-associated gene. Overall, 13% of patients carried more than one genetic variant (pathogenic or VUS). Patients with ALS carrying two variants developed disease at a significantly earlier age compared with patients with a single variant (median age of onset=56 vs 60 years, p=0.0074). Conclusions: Routine screening for ALS-associated pathogenic mutations in a specialised ALS referral clinic will impact clinical care in 21% of cases. An additional 21% of patients have variants in the ALS gene panel currently of unconfirmed significance after removing non-specific or predicted benign variants. Overall, variants within known ALS-linked genes are of potential clinical importance in 42% of patients. |
URI: | https://www.um.edu.mt/library/oar/handle/123456789/103517 |
Appears in Collections: | Scholarly Works - FacM&SPB |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Value_of_systematic_genetic_screening_of_patients_with_amyotrophic_lateral_sclerosis.pdf | 1.27 MB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.